During the past 10 years, preclinical studies implicating sustained androgen receptor (AR)
signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to …

Owing to the development of multiple novel therapies, there has been major progress in the
treatment of advanced prostate cancer over the last two decades; however, the disease …

Prostate cancer is a hormone-dependent malignancy, whose onset and progression are
closely related to the activity of the androgen receptor (AR) signaling pathway. Due to this …

Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC),
especially those that are consequences of treatment-induced suppression of the androgen …

Metastatic castration-resistant prostate cancer (CRPC) is associated with substantial clinical,
pathologic, and molecular heterogeneity. Most tumors remain driven by androgen receptor …

While there are myriad mechanisms of primary and acquired resistance to conventional and
next-generation hormonal therapies in prostate cancer, the potential role of androgen …

In the past decade, remarkable progress in cancer medicine has been achieved by the
development of treatments that target DNA sequence variants. However, a purely genetic …

Background: Advanced prostate cancer is a phenotypically diverse disease that evolves
through multiple clinical courses. PSA level is the most widely used parameter for disease …

The term aggressive variant prostate cancer (AVPCa) refers to androgen receptor (AR)-
independent anaplastic forms of prostate cancer (PCa), clinically characterized by a rapidly …

Summary Background The E1A-associated protein p300 (p300) has emerged as a
promising target for cancer therapy due to its crucial role in promoting oncogenic signaling …